Eylea Market Growth Through 2030 Creates New Strategic Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Eylea Market Growth Potential: How Will Market Size Change Through 2030?
The market for Eylea has experienced robust expansion in recent years, with projections indicating an increase from $10.51 billion in 2025 to $11.15 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.2%. This historical growth has been driven by several factors, including a higher incidence of age-related macular degeneration, an aging worldwide population, the proven clinical effectiveness of anti-VEGF medications, a growing number of specialized ophthalmology clinics, and favorable reimbursement policies for retinal treatments.
The Eylea market is anticipated to experience robust expansion in the coming years, with projections indicating it will reach a value of $14.79 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.3%. This upward trajectory during the forecast period is largely fueled by factors such as the rising number of individuals with diabetes, broader applications in treating various retinal conditions, the development of long-acting formulations, enhancements in drug delivery methods, and greater accessibility in emerging markets. Key trends shaping this period include a growing emphasis on extended-interval anti-VEGF therapies, a notable shift toward the adoption of prefilled syringes, an expanding role in managing diabetic retinopathy, a rise in hospital-based intravitreal procedures, and an increased focus on collecting real-world evidence to assess treatment outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
Eylea Market Development Factors: Which Trends Are Supporting Demand?
The rising incidence of eye disorders is anticipated to boost the Eylea market. Ocular diseases are conditions that impair the eye’s normal function, diminishing vision and clarity. Often, these conditions remain asymptomatic until they reach an advanced stage. Eylea is used to treat disorders such as wet age-related macular degeneration (AMD) and glaucoma, both of which damage the retina or macula and compromise eyesight. It works by inhibiting a protein responsible for forming new, fragile blood vessels and reducing swelling in the retina caused by vascular blockages. For example, data from the BrightFocus Foundation—a U.S. nonprofit focused on macular degeneration and glaucoma research—indicated in 2024 that roughly 80 million people worldwide have glaucoma, with that number expected to climb to 111 million by 2040. Consequently, the growing prevalence of ocular diseases is fueling expansion in the Eylea market.
Eylea Market Segmentation And Category Breakdown
The eylea market covered in this report is segmented –
1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications
Subsegments:
1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes
2) By Vial Package: Single-Dose Vials, Multi-Dose Vials
Eylea Market Transformation Trends: Which Innovations Are Driving Change?
Leading firms within the eylea market are emphasizing the development of biologic therapies, particularly aflibercept biosimilars, to secure a strategic edge. Aflibercept Biosimilar represents a biologically analogous version of the original aflibercept drug, ensuring no clinically significant differences while providing a more economical option for managing certain ocular disorders. As an example, Biocon Biologics Ltd., a biopharmaceutical company headquartered in India, obtained marketing approval from the European Commission (EC) in September 2023 for YESAFILI, a biosimilar of Aflibercept, across the European Union (EU). This authorization followed a favorable assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July. YESAFILI, an ophthalmologic treatment for multiple eye conditions, has been affirmed as comparable to the reference product Eylea (aflibercept) in terms of quality, safety, and effectiveness.
Eylea Market Competitive Analysis Of Major Industry Participants
Major companies operating in the eylea market are Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Alcon Inc., Genentech Inc., Johnson & Johnson, Samsung Bioepis Co. Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Aerie Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Allergan plc, BioMarin Pharmaceutical Inc.
Access The Complete Eylea Market Report:
Eylea Market Regional Analysis And Leading Geography
North America was the largest region in the eylea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
